Dopamine β-hydroxylase shapes intestinal inflammation through modulating T cell activation

Area of Science:

• Neuroscience
• Immunology
• Gastroenterology

Background:

• Inflammatory bowel disease (IBD) involves chronic intestinal inflammation and immune dysfunction.
• The enteric nervous system and neuro-immune interactions are implicated in IBD pathogenesis.
• The role of dopamine beta-hydroxylase (DBH) in intestinal inflammation is not well understood.

Purpose of the Study:

• To investigate the therapeutic effects of DBH inhibition on experimental colitis.
• To explore the impact of DBH inhibition on immune cell function and neurotransmitter levels in IBD.

Main Methods:

• DBH inhibition using nepicastat in mouse models of colitis (T cell transfer, DNBS, DSS).
• Assessment of disease severity, mucosal ulceration, and T cell function.
• Analysis of pro-inflammatory mediators, T cell subsets (Th1, Th17, Tregs), and dopamine/norepinephrine levels.

Main Results:

• Nepicastat treatment ameliorated chronic and acute experimental colitis, reducing disease activity and colon shortening.
• DBH inhibition led to decreased pro-inflammatory cytokines (TNF-α, IL-6, IFN-γ) and rebalanced T cell populations.
• Inhibition of dopamine to norepinephrine conversion increased dopamine levels and decreased norepinephrine levels, with observed immune-modulatory effects.

Conclusions:

• Modulating neurotransmitter levels by inhibiting DBH offers protective effects against colitis progression.
• DBH inhibition impacts the neuro-immune axis, suggesting a novel therapeutic strategy for IBD.
• Targeting DBH presents a promising approach for attenuating intestinal inflammation.